ArticleNature communications2025
Alternating current pre-treatment enhances multi-enzymatic activity of high-entropy alloy nanozymes that regulate metabolism for effective tumor immunotherapy.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Immunomodulatory Nanozymes as Programmable Redox-Immune Set-Point Regulators.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Electric Field-Empowered Nanozymes: From Passive Adaptation to Active Precision Therapy.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- From energy metabolic homeostasis to immune remodeling: the role and therapeutic potential of STING signaling in the tumor microenvironment.Cell communication and signaling : CCS · 2026Review
- Microneedle patches deliver targeted GLP-1RAs-loaded nanoparticles for the treatment of rheumatoid arthritis.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Nanozymes capable of inducing metabolic reprogramming and activating the immune response without external stimuli in vivo are highly pursued for malignant tumor therapy. In this paper, a PtIrFeMoZn high-entropy alloy (HEA) nanozyme is designed and synthesized via a simple one-step hydrothermal method. The HEA nanozymes not only trigger apoptosis and ferroptosis via cascade biocatalysis, thereby enhancing immunogenicity, but also enhance the immune effect by targeting the glycolytic pathway. It is worth mentioning that a simple pre-treatment of nanozymes by alternating current (AC) yielded much better therapeutic and immuno-effect. The 'AC-treated' nanozymes exhibit an excellent synergy of peroxidase-like (POD-like), myeloperoxidase-like (MPO-like), and glutathione peroxidase-like (GPx-like) activities, generating a sufficient reactive oxygen species (ROS) storm. Additionally, two immune pathways (ICD and the cGAS-STING) are activated simultaneously. Furthermore, the production of HClO and the depletion of NADH can regulate metabolism, further disrupting the equilibrium of the glycolysis process. This not only increases the cell death but also enhances the immune response in female tumor-bearing mice. This study proposes a multi-pronged therapeutic strategy that can significantly activate anti-tumor immunotherapeutic effects through ROS storm, GSH/NADH oxidation, and lactate/ATP depletion, triggering apoptosis/ferroptosis/immunotherapy. These findings hold significant promise for inspiring the development of HEA nanozymes for tumor immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.